Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

被引:51
作者
Ardeshna, KM [1 ]
Kakouros, N
Qian, W
Powell, MG
Saini, N
D'Sa, S
Mackinnon, S
Hoskin, PJ
Goldstone, AH
Linch, DC
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] UCL Hosp, Dept Haematol, London, England
[3] MRC, Clin Trials Unit, London, England
关键词
salvage chemotherapy; non-Hodgkin's lymphoma; Hodgkin's Lymphoma; autologous stem cell transplant; inadequate partial response;
D O I
10.1111/j.1365-2141.2005.05603.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to determine the outcome of patients with relapsed or refractory lymphoma who have an inadequate response to first- line salvage therapy (1 degrees ST) and who subsequently receive a second-line salvage regimen (2 degrees ST) with the intention of ultimately proceeding to high-dose therapy. The outcome of 57 patients [ Hodgkin's Lymphoma 17, histologically-aggressive non-Hodgkin's Lymphoma (NHL) 26, histologically-indolent NHL 14] who received more than one modality of conventional- dose salvage therapy was analysed. Sixteen patients had a partial response (PR) to 1 degrees ST, but subsequently received 2 degrees ST because the PR was judged to be inadequate ( iPR) because of persisting disease bulk or marrow infiltration. Of these 16 patients, 10 (63%) continued to respond to 2 degrees ST. Of the 15 patients who had stable disease following 1 degrees ST, 5 (33%) responded to 2 degrees ST. Only one of the 24 (4%) with progressive disease (PD) following 1 degrees ST, responded to 2 degrees ST. 25 of the 57 patients ultimately underwent stem cell transplantation. The 2-year progression-free survival (PFS) and the 3-year overall survival ( OS) for all patients was 24% and 31%, respectively. Long-term survival was highly dependent on response to 1 degrees ST (P = 0.0001); in patients with PD following 1 degrees ST, the PFS and OS at 3 years was only 4%. This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 33 条
  • [21] BEAM CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKINS-LYMPHOMA
    MILLS, W
    CHOPRA, R
    MCMILLAN, A
    PEARCE, R
    LINCH, DC
    GOLDSTONE, AH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 588 - 595
  • [22] DEXA-BEAM IN PATIENTS WITH HODGKINS-DISEASE REFRACTORY TO MULTIDRUG CHEMOTHERAPY REGIMENS - A TRIAL OF THE GERMAN HODGKINS-DISEASE STUDY-GROUP
    PFREUNDSCHUH, MG
    RUEFFER, U
    LATHAN, B
    SCHMITZ, N
    BROSTEANU, O
    HASENCLEVER, D
    HAAS, R
    KIRCHNER, H
    KOCH, P
    KUSE, R
    LOEFFLER, M
    DIEHL, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 580 - 586
  • [23] HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION AFTER FAILURE OF CONVENTIONAL CHEMOTHERAPY IN ADULTS WITH INTERMEDIATE-GRADE OR HIGH-GRADE NON-HODGKINS-LYMPHOMA
    PHILIP, T
    ARMITAGE, JO
    SPITZER, G
    CHAUVIN, F
    JAGANNATH, S
    CAHN, JY
    COLOMBAT, P
    GOLDSTONE, AH
    GORIN, NC
    FLESH, M
    LAPORTE, JP
    MARANINCHI, D
    PICO, J
    BOSLY, A
    ANDERSON, C
    SCHOTS, R
    BIRON, P
    CABANILLAS, F
    DICKE, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (24) : 1493 - 1498
  • [24] AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA
    PHILIP, T
    GUGLIELMI, C
    HAGENBEEK, A
    SOMERS, R
    VANDERLELIE, H
    BRON, D
    SONNEVELD, P
    GISSELBRECHT, C
    CAHN, JY
    HAROUSSEAU, JL
    COIFFIER, B
    BIRON, P
    MANDELLI, F
    CHAUVIN, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) : 1540 - 1545
  • [25] The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups
    Prince, HM
    Imrie, K
    Crump, M
    Stewart, AK
    Girouard, C
    Colwill, R
    Brandwein, J
    Tsang, RW
    Scott, JG
    Sutton, DMC
    Pantalony, D
    Carstairs, K
    Sutcliffe, SB
    Keating, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) : 880 - 889
  • [26] 100 AUTOTRANSPLANTS FOR RELAPSED OR REFRACTORY HODGKINS-DISEASE AND LYMPHOMA - VALUE OF PRETRANSPLANT DISEASE STATUS FOR PREDICTING OUTCOME
    RAPOPORT, AP
    ROWE, JM
    KOUIDES, PA
    DUERST, RA
    ABBOUD, CN
    LIESVELD, JL
    PACKMAN, CH
    EBERLY, S
    SHERMAN, M
    TANNER, MA
    CONSTINE, LS
    DIPERSIO, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) : 2351 - 2361
  • [27] Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
    Schmitz, N
    Pfistner, B
    Sextro, M
    Sieber, M
    Carella, AM
    Haenel, M
    Boissevain, F
    Zschaber, R
    Müller, P
    Kirchner, H
    Lohri, A
    Decker, S
    Koch, B
    Hasenclever, D
    Goldstone, AH
    Diehl, V
    [J]. LANCET, 2002, 359 (9323) : 2065 - 2071
  • [28] High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
    Schouten, HC
    Qian, W
    Kvaloy, S
    Porcellini, A
    Hagberg, H
    Johnsen, HE
    Doorduijn, JK
    Sydes, MR
    Kvalheim, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3918 - 3927
  • [29] Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma.: Results of a single-centre study of 65 patients
    Soussain, C
    Souleau, B
    Gabarre, J
    Zouabi, H
    Sutton, L
    Boccaccio, C
    Albin, N
    Charlotte, F
    Merle-Béral, H
    Delort, J
    Binet, JL
    Leblond, V
    [J]. LEUKEMIA & LYMPHOMA, 1999, 33 (5-6) : 543 - 550
  • [30] High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation
    Sweetenham, JW
    Carella, AM
    Taghipour, G
    Cunningham, D
    Marcus, R
    Della Volpe, A
    Linch, DC
    Schmitz, N
    Goldstone, AH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3101 - 3109